Publications by authors named "D Bradley Dyke"

Chronic lymphocytic leukemia (CLL) is characterized by multiple copy number alterations (CNAs) and somatic mutations that are central to disease prognosis, risk stratification, and mechanisms of therapy resistance. Fluorescence in situ hybridization (FISH) panels are widely used in clinical applications as the gold standard for screening prognostic chromosomal abnormalities in CLL. DNA sequencing is an alternative approach to identifying CNAs but is not an established method for clinical CNA screening.

View Article and Find Full Text PDF
Article Synopsis
  • TP53 abnormalities, including mutations and 17p deletions, are critical prognostic indicators in chronic lymphocytic leukemia (CLL) and high count monoclonal B-cell lymphocytosis (HCMBL) but were less researched in HCMBL.
  • In a study of 1,230 newly diagnosed individuals, 7.5% of CLL and 4.5% of HCMBL showed TP53 mutations, with most patients being wild-type (91.7%).
  • Greater numbers of TP53 abnormalities correlated with an increased risk of needing treatment and higher mortality rates, emphasizing the importance of measuring both mutations and deletions for prognosis in CLL and HCMBL.
View Article and Find Full Text PDF

Background: Dental caries is a prevalent, complex, chronic illness that is avoidable. Better dental health outcomes are achieved as a result of accurate and early caries risk prediction in children, which also helps to avoid additional expenses and repercussions. In recent years, artificial intelligence (AI) has been employed in the medical field to aid in the diagnosis and treatment of medical diseases.

View Article and Find Full Text PDF

Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these patients is necessary to establish a benchmark for evaluating novel agents currently available and in development. We evaluated outcomes of 144 patients with CLL treated at Mayo Clinic with 2018 iwCLL disease progression on ibrutinib.

View Article and Find Full Text PDF